Context Therapeutics Inc (NASDAQ: CNTX)’s stock price has dropped by -7.07 in relation to previous closing price of 1.84. Nevertheless, the company has seen a loss of -13.64% in its stock price over the last five trading days. globenewswire.com reported 2024-09-23 that Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $118.5 million, plus royalties on net sales Context anticipated IND filing for BA3362 in mid-2026 SAN DIEGO and PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) — BioAtla, Inc. (“BioAtla”) (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (“CAB”) antibody therapeutics for the treatment of solid tumors, and Context Therapeutics Inc. (“Context”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the companies have entered into an agreement under which Context has obtained from BioAtla an exclusive, worldwide license to develop, manufacture and commercialize BA3362, BioAtla’s Nectin-4 x CD3 TCE.
Is It Worth Investing in Context Therapeutics Inc (NASDAQ: CNTX) Right Now?
The 36-month beta value for CNTX is also noteworthy at 2.27. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CNTX is 59.34M, and at present, short sellers hold a 1.84% of that float. The average trading volume of CNTX on October 11, 2024 was 181.70K shares.
CNTX’s Market Performance
The stock of Context Therapeutics Inc (CNTX) has seen a -13.64% decrease in the past week, with a -20.09% drop in the past month, and a -15.35% fall in the past quarter. The volatility ratio for the week is 7.21%, and the volatility levels for the past 30 days are at 8.92% for CNTX. The simple moving average for the past 20 days is -12.82% for CNTX’s stock, with a 0.99% simple moving average for the past 200 days.
Analysts’ Opinion of CNTX
Many brokerage firms have already submitted their reports for CNTX stocks, with Piper Sandler repeating the rating for CNTX by listing it as a “Overweight.” The predicted price for CNTX in the upcoming period, according to Piper Sandler is $4.50 based on the research report published on May 16, 2024 of the current year 2024.
CNTX Trading at -22.90% from the 50-Day Moving Average
After a stumble in the market that brought CNTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.82% of loss for the given period.
Volatility was left at 8.92%, however, over the last 30 days, the volatility rate increased by 7.21%, as shares sank -20.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.83% lower at present.
During the last 5 trading sessions, CNTX fell by -13.64%, which changed the moving average for the period of 200-days by +55.45% in comparison to the 20-day moving average, which settled at $1.9615. In addition, Context Therapeutics Inc saw 51.33% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CNTX
Current profitability levels for the company are sitting at:
- -1056.66 for the present operating margin
- 0.43 for the gross margin
The net margin for Context Therapeutics Inc stands at -979.68. The total capital return value is set at -0.2. Equity return is now at value -29.68, with -28.46 for asset returns.
Currently, EBITDA for the company is -25.06 million with net debt to EBITDA at 5.07. When we switch over and look at the enterprise to sales, we see a ratio of 1409.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 64.01.
Conclusion
In summary, Context Therapeutics Inc (CNTX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
